Table 1.
Characteristics of included studies for detecting pathologic response to neoadjuvant chemotherapy.
| Author | County | Year | Study design | Number of patients | Mean age | Type of NAC | Cycles of NAC | Evaluation time | Endpoint | pCR/npCR | Evaluation index | Sen. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pengel et al. [23] | Netherlands | 2014 | Pro. | 93 | 47.8 | Trastuzumab-based regimen | 3 or 6 | B/A (1 or 3 cycles) | pCR | 43/50 | MRI PET/CT |
0.465 0.860 |
| Kim et al. [22] | Korea | 2014 | Retro. | 59 | 46.6 | NR | 3 or 6 | B/A (3 or 6 cycles) | Miller and Payne system | 34/22 23/15 |
MRI PET/CT |
0.912 0.913 |
| Tateishi et al. [21] | Japan | 2012 | Retro. | 142 | 57 | 5-Fluorouracil, epirubicin, cyclophosphamide, and so forth | 4 | B/A (2 cycles) | pCR | 24/118 | MRI PET/CT |
0.50 0.667 |
| Park et al. [20] | Korea | 2011 | Retro. | 32 | 45 | Doxorubicin and docetaxel | 3 or 6 | B/A (18–22 days) | pCR | 8/24 | MRI PET/CT |
0.625 1 |
| Choi et al. [19] | Korea | 2010 | Pro. | 41 | 45.1 | Adriamycin and cyclophosphamide or docetaxel | 3 or 8 | B/A (3 or 8 cycles) | pCR | 7/34 | MRI PET/CT |
0.714 0.857 |
| Chen et al. [18] | USA | 2004 | Pro. | 15 | 44 | Anthracycline-based regimen | NR | B/A | pCR | 10/6 | MRI PET/CT |
0.333 0.90 |
NR: not reported.
B/A: before or after the NAC.
pCR: pathology complete response.
Pro.: prospect. Retro.: retrospect.